newsfilter
← Latest News
GlobeNewswire·

ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026

MELBOURNE, Australia and INDIANAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that safety and tolerability data from the ProstACT Global Phase 3